Related Articles
Prognostic value of EGFR 19‑del and 21‑L858R mutations in patients with non‑small cell lung cancer
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations
Concurrent TP53 mutations predict a poor prognosis of EGFR‑mutant NSCLCs treated with TKIs: An updated systematic review and meta‑analysis
Association between epidermal growth factor receptor gene mutation status and short‑term efficacy of first‑line platinum‑containing chemotherapy in advanced non‑small cell lung cancer
Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR‑TKI treatment in advanced NSCLC